In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Medarex: A Transformational Acquisition Rooted In Collaboration

Executive Summary

Bristol's $2.4 billion buyout of Medarex in 2009 yielded value equivalent or greater to that realized in larger M&A transactions signed that year, such as Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech. The deal made BMS a leader in immuno-oncology and by most accounts is the highlight of the pharma's "string of pearls" strategy.

Advertisement

Related Content

Post-MYSTIC, Bristol Renews CTLA-4 Vows, But Is "Not Wedded" In Lung Cancer
Keytruda And The Surprising Fruits Of M&A
Bristol Looking For Deals, Immuno-Oncology And Otherwise
BMS Adds To String Of Pearls: $470 Mil. Deal With French Biotech Brings Innate Immunity Approach Into Its R&D Pipeline
With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV005175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel